您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Brilaroxazine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Brilaroxazine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Brilaroxazine图片
规格:98%
分子量:450.36
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
Brilaroxazine (RP5603) 是一种有效的具有口服活性的多巴胺/5-羟色胺 (dopamine (DA)/5-HT) 调节剂。Brilaroxazine 是多巴胺 (DA) D2,D3 和 D4 受体,血清素 5-HT1A (Ki=1.5 nM) 和 5-HT2A (Ki=2.5 nM) 的部分激动剂,对 5-HT2B (Ki=0.19 nM) 和 5-HT7?(Ki=2.7 nM) 受体具有拮抗剂活性。Brilaroxazine 是一种非典型抗精神病试剂,在动物模型中,具有改善神经精神病和神经疾病的认知障碍的潜力。
货号:ajcx38078
CAS:1239729-06-6
分子式:C22H25Cl2N3O3
分子量:450.36
溶解度:DMSO : 100 mg/mL (222.04 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].

Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[1].

[1]. Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
[2]. Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.Eur J Pharmacol. 2018 May 15;827:159-166.
[3]. L. Bhat,et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.